Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Tefferi
Ayalew
A
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. tefferi.ayalew@mayo.edu
D017677:Age Distribution; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D000077588:Deferasirox; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D016019:Survival Analysis; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D013792:Thalidomide; D000077269:Lenalidomide; D001374:Azacitidine; D000077588:Deferasirox